CRISPR Gene Editing Breakthrough Saves Baby with Ultra-Rare Metabolic Disorder
• Doctors at Children's Hospital of Philadelphia successfully treated a baby with severe CPS1 deficiency using a personalized CRISPR base-editing therapy, marking a first-of-its-kind approach for this rare metabolic disorder.
• The experimental treatment, developed within just six months of diagnosis, corrected the infant's specific genetic mutation by delivering edited DNA to liver cells via lipid nanoparticles, allowing him to reduce medication and process more dietary protein.
• This breakthrough demonstrates the potential for creating customized gene therapies for millions with rare genetic diseases, with researchers suggesting costs comparable to liver transplantation and possibilities for treating numerous other conditions.
Gensaic and Novo Nordisk Partner to Develop Novel Precision Therapeutics Platform
• Gensaic and Novo Nordisk have formed a strategic collaboration to develop next-generation precision therapeutics, combining Gensaic's innovative delivery platform with Novo's therapeutic expertise.
• The partnership aims to advance novel treatment approaches across multiple therapeutic areas, leveraging advanced drug delivery technologies to enhance therapeutic efficacy and patient outcomes.
• This collaboration represents a significant step forward in precision medicine development, with potential applications in metabolic disorders and other chronic diseases.
Plasmid DNA Manufacturing Market Set to Reach $11.33 Billion by 2034 Amid Gene Therapy Boom
• The global plasmid DNA manufacturing market is projected to grow from $2.64 billion in 2025 to $11.33 billion by 2034, representing a robust CAGR of 17.92%.
• North America leads the market with $960 million in 2024, driven by biopharmaceutical industry presence, high disposable income, and advanced healthcare infrastructure.
• Artificial intelligence is revolutionizing plasmid DNA production through computational modeling, improving CRISPR/Cas systems, and developing novel vectors for gene therapy applications.
NHS England Approves Gene-Editing Therapy Casgevy for Severe Sickle Cell Disease
• NHS England approves Casgevy, a gene-editing therapy, for treating severe sickle cell disease in eligible patients aged 12 and over.
• Casgevy, also known as exa-cel, modifies a patient's stem cells to produce healthy red blood cells, potentially curing the disease.
• Clinical trials showed that Casgevy significantly reduced hospitalizations, offering a 'functional cure' for nearly all participants.
• The treatment will be available at specialist NHS centers, providing hope for improved quality of life for sickle cell patients.
Breakthrough Medications Show Promise in Reducing Lipoprotein(a) Levels by Up to 90%
• Two novel therapies - oral muvalaplin and injectable zerlasiran - demonstrate remarkable efficacy in lowering lipoprotein(a) levels by 80-90% with minimal side effects in clinical trials.
• The oral medication muvalaplin works by preventing apolipoprotein B and apolipoprotein A molecules from binding, while zerlasiran uses small interfering RNA to target the underlying gene.
• These developments represent a significant advancement in cardiovascular medicine, as elevated lipoprotein(a) is a genetically determined risk factor that previously had no effective treatment options.
Intellia Therapeutics Initiates Phase 3 Trial of NTLA-2002 for Hereditary Angioedema
• Intellia Therapeutics has dosed the first patient in its Phase 3 HAELO trial evaluating NTLA-2002 for hereditary angioedema (HAE).
• The HAELO trial is a global, randomized, double-blind, placebo-controlled study involving 60 adults with Type I or Type II HAE.
• NTLA-2002, a single-dose CRISPR-based therapy, targets the _KLKB1_ gene to reduce plasma kallikrein activity and prevent HAE attacks.
• Intellia anticipates completing enrollment in the second half of 2025 and plans for a potential U.S. launch in 2027, pending regulatory approval.
© Copyright 2025. All Rights Reserved by MedPath